Phaseline

Targets › GLRA1

GLRA1 (Glycine receptor subunit alpha-1): drug programs, companies and trials

7 programs from 7 companies in 15 trials: 8 Phase 4, 5 Phase 3, 2 Phase 2; Neurology, Cardiovascular, Psychiatry; next expected readout Nov 2026.

Subunit of heteromeric glycine-gated chloride channels. Plays an important role in the down-regulation of neuronal excitability. (UniProt, P23415)

Open in Phaseline: the race on GLRA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kaohsiung Medical University Chung-Ho Memorial HospitalSevoflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Lung Cancer; Hepatocellular Carcinoma; Ovarian CancerNov 2026
PharmasoftGlycine
Glycine receptor agonist
GLRA1Phase 4Ischemic StrokeApr 2027
Medical University of ViennaDesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Postoperative DeliriumDec 2027
Georgia TsaousiDesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 4Brain Edema Caused by Drugs–
Xijing Hospitaldesflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 3Cardiac SurgeryDec 2028
Sedana MedicalIsoflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 3Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium …–
NeuroRxNRX-101
D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant
GLRA1, HTR2APhase 2Treatment Resistant DepressionDec 2027

Conditions

Lung Cancer (1) Hepatocellular Carcinoma (1) Ovarian Cancer (1) Ischemic Stroke (1) Postoperative Delirium (1) Treatment Resistant Depression (1) Cardiac Surgery (1) Brain Edema Caused by Drugs (1) Post-Intensive Care Syndrome (1) Diabete Mellitus (1) Sedation (1) Prevention of Delirium (1)

Modalities

small molecule (7)

Companies

Kaohsiung Medical University Chung-Ho Memorial Hospital (1) Pharmasoft (1) Medical University of Vienna (1) NeuroRx (1) Xijing Hospital (1) Georgia Tsaousi (1) Sedana Medical (1)

Related targets

GLRB (5) GABRA1 (5) GABRB2 (5) GABRG2 (5) HTR2A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.